Table D.3 (*Continued*)

Reference	Species/tissue	Test agent	Treatment regimen	Results/comments
[79]	Mouse; maternal bone marrow, fetal blood	Diethylstilbestrol	i.p. injection on 15th–16th day of gestation	Increased MN in fetal blood, but only marginal in maternal bone marrow
[143]	Mouse; 4-day embryo (blastocysts or morulas)	Acrylamide	i.p. injection for 5 consecutive days. Untreated C3H/J female mice were mated with treated C57BL/6J mice 5–17 days after the end of treatment to sample various post-meiotic cells: spermatozoa (days 5–7), late spermatids (days 8–10) and mid + late spermatids (days 112118).	Increased MN in morphologically normal and abnormal embryos, respectively (41 and 93 MN per 1000 cells)
[144]	Mouse (pregnant female); 3-day embryo	Trichlorfon	i.p. injection at 6 h post-presumed conception and either sacrificed on day of gestation (dg) 3, 9 or 17.	Increased MN in embryos at dg 3.
[145]	Mouse (pregnant female); 3-day embryo (blastocysts)	Chlorpyrifos	i.p. injection on day 0 of pregnancy. Evaluated on day 3 of gestation.	Increased MN per embryo and the percentages of embryos with at least one MN.

MMS, methyl methanesulfonate; MMC, mitomycin C; B[*a*]p, benzo[*a*]pyrene; DEN, diethylnitrosamine; MNNG, *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine; DMBA, 7,12-dimethylbenz[*a*]anthracene.

References

[1] S. Galloway, Commentary on special issue "Report of the International Workshop on Standardisation of Genotoxicity Test Procedures", Mutat. Res. 312 (1994) 201–203.

[2] M. Hayashi, R.R. Tice, J.T. MacGregor, D. Anderson, D.H. Blakey, M. Kirsch-Volders, F.B. Oleson Jr., F. Pacchierotti, F. Romagna, H. Shimada, S.S. Sutou, B. Vannier, *In vivo* rodent erythrocyte micronucleus assay, Mutat. Res. 312 (1994) 293–304.

[3] M. Hayashi, J.T. MacGregor, D.G. Gatehouse, I.-D. Adler, D.H. Blakey, S.D. Dertinger, G. Krishna, T. Morita, A. Russo, S. Sutou, In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring, Environ, Mol. Mutagen. 35 (2000) 234–252.

[4] K.J. Hutter, M. Stöhr, Rapid detection of mutagen induced micronucleated erythrocytes by flow cytometry, Histochemistry 75 (1982) 353–362.

[5] F. Romagna, C.D. Staniforth, The automated bone marrow micronucleus test, Mutat. Res. 213 (1989) 91–104.

[6] M. Hayashi, H. Norppa, T. Sofuni, M. Ishidate Jr., Mouse bone marrow micronucleus test using flow cytometry, Mutagenesis 7 (1992) 251–256.

[7] M. Hayashi, H. Norppa, T. Sofuni, M. Ishidate Jr., Flow cytometric micronucleus test with mouse peripheral erythrocytes, Mutagenesis 7 (1992) 257–264.

[8] J. Grawé, G. Zetterberg, H. Amneus, Flow-cytometric enumeration of micronucleated polychromatic erythrocytes in mouse peripheral blood, Cytometry 13 (1992) 750–758.

[9] G. Krishna, D. Brott, G. Urda, M. McKeel, J. Zandee, J. Theiss, Comparative micronucleus quantitation in pre- and post-column fractionated mouse bone marrow by manual and flow methods, Mutat. Res. 302 (1993) 119–127.

[10] G. Krishna, K. Criswell, D. Zielinski, G. Urda, P. Juneau, M. Bleavins, J. Theiss, Validation of micronucleus evaluation in the rat using flow cytometry with five model compounds, Environ. Mol. Mutagen. 31 (Suppl. 29) (1998) 46 (abstract).

[11] G. Krishna, G. Urda, J. Theiss, Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: A pharmaceutical industry perspective, Environ. Mol. Mutagen. 32 (1998) 115–120.

[12] A.M. Tometsko, D.K. Torous, S.D. Dertinger, Analysis of micronucleated cells by flow cytometry. 3. Advanced technology for detecting clastogenic activity, Mutat. Res. 292 (1993) 145–153.

[13] J.W. Parton, W.P. Hoffman, M.L. Garriott, Validation of an automated image analysis micronucleus scoring system, Mutat. Res. 370 (1996) 65–73.

[14] S.D. Dertinger, D.K. Torous, K.R. Tometsko, Simple and reliable enumeration of micronucleated reticulocytes with a single-laser flow cytometer, Mutat. Res. 371 (1996) 283–292.

[15] S.D. Dertinger, Y. Chen, R.K. Miller, K.J. Brewer, T. Smudzin, D.K. Torous, N.E. Hall, K.A. Olvany, F.G. Murante, C.R. Tometsko, Micronucleated CD71-positive reticulocytes: A blood-based endpoint of cytogenetic damage in humans, Mutat. Res. 542 (2003) 77–87.

[16] K. Criswell, G. Krishna, D. Zielinski, G. Urda, J. Theiss, P. Juneau, M. Bleavins, Use of acridine orange in flow cytometric evaluation of erythropoietic cytotoxicity, Mutat. Res. 414 (1998) 49–61.

[17] K. Criswell, G. Krishna, D. Zielinski, G. Urda, J. Theiss, P. Juneau, M. Bleavins, Use of acridine orange in flow cytometric assessment of micronuclei induction, Mutat. Res. 414 (1998) 63–75.

[18] K. Criswell, G. Krishna, D. Zielinski, G. Urda, P. Juneau, S. Bulera, M. Bleavins, Validation of a flow cytometric acridine orange micronuclei methodology in rats, Mutat. Res. 528 (2003) 1–18.

[19] N. Asano, Y. Katsuma, T. Hironobu, N. Higashikuni, M. Hayashi, An automated new technique for scoring rodent micronucleus assay: computerized image analysis of acridine orange supravitally stained peripheral blood cells, Mutat. Res. 404 (1998) 149–154.

[20] L. Abramsson-Zetterberg, J. Grawé, G. Zetterberg, Flow cytometric analysis of micronucleus induction in mice by internal exposure to 137 Cs at very low dose rates, Int. J. Radiat. Biol. 67 (1995) 29–36.

[21] J. Grawé, L. Abramsson-Zetterberg, G. Zetterberg, Low dose effects of chemicals as assessed by the flow cytometric in vivo micronucleus assay, Mutat. Res. 405 (1998) 199–208.

[22] L. Abramsson-Zetterberg, The dose–response relationship at very low doses of acrylamide is linear in the flow cytometer-based mouse micronucleus assay, Mutat. Res. 535 (2003) 215–222.

[23] D. Torous, N. Asano, C. Tometsuko, S. Sugunan, S. Dertinger, T. Morita, M. Hayashi, Performance of flow cytometric analysis for the micronucleus assay—a reconstruction model using serial dilutions of malaria-infected cells with normal mouse peripheral blood, Mutagenesis 21 (2006) 11–13.

[24] D.K. Torous, N.E. Hall, A.H. Illi-Love, M.S. Diehl, K. Cederbrant, K. Sandelin, I. Pontén, G. Bolcsfoldi, L.R. Ferguson, A. Pearson, J.B. Majeska, J.P. Tarca, G.M. Hynes, A.M. Lynch, J.P. McNamee, P.V. Bellier, M. Parenteau, D. Blakey, J. Bayley, B.M. van der Leede, P. Vanparys, P.R. Harbach, S. Zhao, A.L. Filipunas, C.W. Johnson, C.R. Tometsko, S.D. Dertinger, Inter-laboratory validation of a CD71-based flow cytometric method (MicroFlow®) for the scoring of micronucleated reticulocytes in mouse peripheral blood, Environ. Mol. Mutagen. 45 (2005) 44–55.

[25] N. Asano, D.K. Torous, C.R. Tometsko, S.D. Dertinger, T. Morita, M. Hayashi, Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine, Mutagenesis 21 (2006) 15–20.

[26] S.D. Dertinger, M.E. Bishop, J. McNamee, M. Hayashi, T. Suzuki, N. Asano, M. Nakajima, A. Wakata, M.M. Moore, D.K. Torous, J.T. MacGregor, Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: I. Intra- and inter-laboratory comparison with microscopic scoring, Toxicol. Sci. 94 (1) (2006) 83–91, Epub 2006 Aug 3.

[27] J.T. MacGregor, M.E. Bishop, J. McNamee, M. Hayashi, N. Asano, A. Wakata, M. Nakajima, A. Aidoo, M.M. Moore, S.D. Dertinger, Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: II. An efficient method of monitoring chromosomal damage in the rat, Toxicol. Sci. 94 (1) (2006) 92–107, Epub 2006 Aug 3.

[28] D.K. Torous, N.E. Hall, S.D. Dertinger, M. Diehl, A.H. Illi-Love, K. Cederbrant, K. Sandelin, G. Bolcsfoldi, L.R. Ferguson, A. Pearson, J.B. Majeska, J.P. Tarca, D.R. Hewish, L. Doughty, M. Fenech, J.L. Weaver, D.D. Broud, D.G. Gatehouse, G.M. Hynes, P. Kwanyuen, J. McLean, J.P. McNamee, M. Parenteau, V. Van Hoof, P. Vanparys, M. Lenarczyk, J. Siennicka, B. Litwinska, M.G. Slowikowska, P.R. Harbach, C.W. Johnson, S. Zhao, C.S. Aaron, A.M. Lynch, I.C. Marshall, B. Rodgers, C.R. Tometsko, Flow cytometric enumeration of micronucleated reticulocytes: high transferability among 14 laboratories, Environ. Mol. Mutagen. 38 (2001) 59–68.

[29] FDA (U.S. Food and Drug Administration), Office of Food Additive Safety, Redbook 2000, Toxicological principles for safety assessment of food ingredients, Updated November 2003. www.cfsan.fda.gov/~redbook/red-toca.html.

[30] European Food Safety Authority (EFSA), Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food on a request from the commission related to semicarbazide in food, Question number EFSA-2003-235, EFSA J. 219 (2005) 1–36.

[31] R. Schlegel, J.T. MacGregor, The persistence of micronuclei erythrocytes in the peripheral circulation of normal and splenectomized Fisher 344 rats: implications for cytogenetic screening, Mutat. Res. 127 (1984) 169–174.

[32] M. Hayashi, Y. Kodama, T. Awogi, T. Suzuki, A.O. Asita, T. Sofuni, The micronucleus assay using peripheral blood reticulocytes from mitomycin C- and cyclophosphamide-treated rats, Mutat. Res. 278 (1992) 209–213.

[33] A. Wakata, Y. Miyamae, S. Sato, T. Suzuki, T. Morita, N. Asano, T. Awogi, K. Kondo, M. Hayashi, Evaluation of the rat micronucleus test with bone marrow and peripheral blood: summary of the 9th collaborative study by CSGMT/JEMS•MMS, Environ. Mol. Mutagen. 32 (1998) 84–100.

[34] S. Hamada, S. Sutou, T. Morita, A. Wakata, S. Asanami, S. Hosoya, S. Ozawa, K. Kondo, M. Nakajima, H. Shimada, K. Osawa, Y. Kondo, N. Asano, S.-I. Sato, H. Tamura, N. Yajima, R. Marshall, C. Moore, D.H. Blakey, J.L. Weaver, D.K. Torus, R. Proudlock, S. Ito, C. Namiki, M. Hayashi, Evaluation of the rodent micronucleus assay by a 28-day-treatment protocol: Summary of the 13th collaborative study by CSGMT/JEMS•MMS, Environ. Mol. Mutagen. 37 (2001) 93–110.

[35] L. Abramsson-Zetterberg, G. Zetterberg, M. Bergqvist, J. Grawé, Human cytogenetic biomonitoring using flow-cytometric analysis of micronuclei in transferrin-positive immature peripheral blood reticulocytes, Environ. Mol. Mutagen. 36 (2000) 22–31.

[36] L. Abramsson-Zetterberg, L.J.K. Durling, F. Yang-Wallentin, E. Rytter, B. Vessby, The impact of folate status and folic acid supplementation on the micronucleus frequency in human erythrocytes, Mutat. Res. 603 (2006) 33–40.

[37] S.D. Dertinger, K. Camphausen, J.T. MacGregor, M.E. Bishop, D.K. Torous, S. Avlasevich, S. Cairns, C.R. Tometsko, C. Menard, T. Muanza, Y. Chen, R.K. Miller, K. Cederbrant, K. Sandelin, I. Pontén, G. Bolcsfoldi, Three-color labeling method for flow cytometric measurement of cytogenetic damage in rodent and human blood, Environ. Mol. Mutagen. 44 (2005) 427–435.

[38] H. Stopper, K. Hempel, C. Reiners, S. Vershenya, R. Lorenz, V. Vukicevic, A. Heidland, J. Grawé, Pilot study for comparison of reticulocyte-micronuclei with lymphocyte-micronuclei in human monitoring, Toxicol. Lett. 156 (2005) 351–360.

[39] J. Grawé, J. Biko, R. Lorenz, C. Reiners, H. Stopper, S. Vershenya, V. Vukicevic, K. Hempel, Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer, Mutat. Res. 583 (2005) 12–25.

[40] J.T. MacGregor, M.E. Bishop, S.D. Dertinger, J. McNamee, M.M. Moore, A. Aidoo, S. Harper, R. Frobish, M. Hayashi, A flow cytometric assay that permits integration of chromoso-

mal damage assessment with routine toxicity testing, in: Annual Meeting, Society of Toxicology, Baltimore, 2004, Abstract.
[41] H. Suzuki, N. Ikeda, K. Kobayashi, Y. Terashima, Y. Shimada, T. Suzuki, T. Hagiwara, S. Hatakeyama, K. Nagaoka, J. Yoshida, Y. Saito, J. Tanaka, M. Hayashi, A study by the Collaborative Study Group for the Micronucleus Test (CSMGT)/Japanese Environmental Mutagen Society (JEMS)-Mammalian Mutagenicity Study Group (MMS), Evaluation of liver and peripheral blood micronucleus assays with 9 chemicals using young rats., Mutat. Res. 583 (2005) 133–145.
[42] W. Ohyama, M. Gonda, H. Miyajima, K. Kondo, T. Noguchi, J. Yoshida, S. Hatakeyama, E. Watabe, Y. Ueno, M. Hayashi, T. Tokumitsu, Collaborative validation study of the in vivo micronucleus test using mouse colonic epithelial cells, Mutat. Res. 518 (2002) 39–45.
[43] T. Nishikawa, M. Haresaku, K. Adachi, M. Masuda, M. Hayashi, Study of a rat skin in vivo micronucleus test: data generated by mitomycin C and methyl methanesulfonate, Mutat. Res. 444 (1999) 159–166.
[44] T. Nishikawa, M. Hasekura, A. Fukushima, T. Nakamura, K. Adachi, M. Masuda, M. Hayashi, Further evaluation of an in vivo micronucleus test on rat and mouse skin: results with five skin carcinogens, Mutat. Res. 513 (2002) 93–102.
[45] T. Noguchi, The development of testis micronucleus test, in: Proceeding of the 26th JEMS Annual Meeting, Hatano, 1997, p. 84, Abstract.
[46] A.D. Tates, I. Neuteboom, M. Hofker, L. den Englse, A micronucleus technique for detecting clastogenic effects of mutagens/carcinogens (DEN, DMN) in hepatocytes of rat liver in vivo, Mutat. Res. 74 (1980) 1–20.
[47] A.D. Tates, I. Neuteboom, A.H. Rotteveel, N. de Vogel, G.J. Menkveld, L. den Engelse, Persistence of preclastogenic damage in hepatocytes of rats exposed to ethylnitrosourea, diethylnitrosamine, dimethylnitrosamine and methyl methanesulphonate. Correlation with DNA O-alkylation, Carcinogenesis 7 (1986) 1053–1058.
[48] I. Cliet, E. Fournier, C. Melcion, A. Cordier, In vivo micronucleus test using mouse hepatocytes, Mutat. Res. 216 (1989) 321–326.
[49] CSGMT, Collaborative Study Group for the Micronucleus Test, Usefulness of mouse liver micronucleus assay, in: Proceeding of the 25th JEMS Annual Meeting, Tokyo, 1996, p. 103, Abstract.
[50] M. Igarashi, H. Shimada, An improved method for the mouse liver micronucleus test, Mutat. Res. 391 (1997) 49–55.
[51] I. Braithwaite, J. Ashby, A non-invasive micronucleus assay in the rat liver, Mutat. Res. 203 (1988) 23–32.
[52] I.V. Uryvaeva, G.V. Delone, An improved method of mouse liver micronucleus analysis: An application to age-related genetic alteration and polyploidy study, Mutat. Res. 334 (1995) 71–80.
[53] A.D. Tates, I. Neuteboom, N. de Vogel, L. den Engelse, The induction of chromosomal damage in rat hepatocytes and lymphocytes, I. Time-dependent changes of the clastogenic effects of diethylnitrosamine, dimethylnitrosamine and ethylmethanesulfonate, Mutat. Res. 107 (1983) 131–151.
[54] J.W. Parton, M.L. Garriott, An evaluation of micronucleus induction in bone marrow and in hepatocytes isolated from collagenase perfused liver or from formalin-fixed liver using four-week-old rats treated with known clastogens Environ, Mol. Mutagen. 29 (1997) 379–385.
[55] T. Shirotori, M. Miyagawa, Investigation of Hepatocyte Micronucleus Assay in Immature Rat: Comparison of the Immature Animal (IA) Method and Partial Hepatectomy (PH) Method, in: Proceeding of the 23rd JEMS Annual Meeting, Fukuoka, 1996, p. 346, Abstract.
[56] H. Suzuki, T. Shirotori, M. Hayashi, A liver micronucleus assay using young rats exposed to diethylnitrosamine: methodological establishment and evaluation, Cytogenet. Genome Res. 104 (2004) 299–303.
[57] P.E. Thomas, L.M. Reik, D.E. Ryan, W. Levin, Regulation of three forms of cytochrome P-450 and epoxide hydrolase in rat liver microsomes, J. Biol. Chem. 256 (1981) 1044–1052.
[58] D.F. Waxman, Rat hepatic cytochrome P-450 isoenzyme 2c, J Biol. Chem. 259 (1984) 15481–15490.
[59] S. Imaoka, S. Fujita, Y. Funae, Age-dependent expression of cytochrome P-450s in rat liver, Biochim. Biophys. Acta. 1097 (1991) 187–192.
[60] B.-J. Song, H.V. Gelboin, S.-S. Park, C.S. Yang, F.J. Gonzalez, Complementary DNA and protein sequences of ethanol-inducible rat and human cytochrome P-450, J. Biol. Chem. 35 (1986) 16689–16697.
[61] F.J. Gonzalez, B.-J. Song, J.P. Hardwick, Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation, Mol. Cell. Biol. 6 (1986) 2969–2976.
[62] J. Lähdetie, M. Parvinen, Meiotic micronuclei induced by X-rays in early spermatids of the rat, Mutat. Res. 81 (1981) 103–115.
[63] A.D. Tates, A.J.J. Dietrich, N. de Vogel, I. Neuteboom, A. Bos, A micronucleus method for detection of meiotic micronuclei in male germ cells of mammals, Mutat. Res. 121 (1983) 131–138.
[64] A.J. Wyrobek, T.E. Schmid, F. Marchetti, Cross-species sperm-FISH assays for chemical testing and assessing paternal risk for chromosomally abnormal pregnancies, Environ. Mol. Mutagen. 45 (2005) 271–283.
[65] A. Naccarati, A. Zanello, S. Landi, R. Consigli, L. Migliore, Sperm-FISH analysis and human monitoring: a study on workers occupationally exposed to styrene, Mutat. Res. 537 (2003) 131–140.
[66] I.D. Adler, T.E. Schmid, A. Baumgartner, Induction of aneuploidy in male mouse germ cells detected by the sperm-FISH assay: a review of the present data base, Mutat. Res. 504 (2002) 173–182.
[67] T.E. Schmid, S. Attia, A. Baumgartner, M. Nuesse, I.D. Adler, Effect of chemicals on the duration of male meiosis in mice detected with laser scanning cytometry, Mutagenesis 16 (2001) 339–343.
[68] T.E. Schmid, X. Lowe, F. Marchetti, J. Bishop, J. Haseman, A.J. Wyrobek, Evaluation of inter-scorer and inter-laboratory reliability of the mouse epididymal sperm aneuploidy (m-ESA) assay, Mutagenesis 16 (2001) 189–195.
[69] T.E. Schmid, W. Xu, I.D. Adler, Detection of aneuploidy by multicolor FISH in mouse sperm after in vivo treatment with acrylamide, colchicine, diazepam or thiabendazole, Mutagenesis 14 (1999) 173–179.
[70] I.D. Adler, J. Bishop, X. Lowe, T.E. Schmid, G. Schriever-Schwemmer, W. Xu, A.J. Wyrobek, Spontaneous rates of sex chromosomal aneuploidies in sperm and offspring of mice: a validation of the detection of aneuploid sperm by fluorescence in situ hybridization, Mutat. Res. 372 (1996) 259–268.
[71] OECD, Guideline for the testing of chemicals. Mammalian erythrocyte micronucleus test, Guideline 474 (July) (1997).
[72] M. Hayashi, T. Sofuni, The need for three dose levels to detect genotoxic chemicals in in vivo rodent assays, Mutat. Res. 327 (1995) 247–251.

[73] T. Suzuki, T. Itoh, M. Hayashi, Y. Nishikawa, F. Furukawa, M. Takahashi, T. Sofuni, Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice, Environ. Mol. Mutagen. 28 (1996) 348–353.
[74] D. Jenssen, C. Ramel, Factors affecting the induction of micronuclei at low doses of X-rays, MMS and dimethylnitrosamine in mouse erythroblasts, Mutat. Res. 58 (1978) 51–65.
[75] J. Ashby, B. Burlinson, P.A. Lefevre, J. Topham, Non-genotoxicity of 2, 4, 6-trinitrotoluene (TNT) to the mouse bone marrow and the rat liver: implications for its carcinogenicity, Arch. Toxicol. 58 (1985) 14–19.
[76] CSGMT, Collaborative Study Group for the Micronucleus Test, Micronucleus test with mouse peripheral blood erythrocytes by acridine orange supravital staining: The summary report of the 5th collaborative study by CSGMT/JEMSMMS, Mutat. Res. 278 (1992, September) 83–98.
[77] T. Shirotori, M. Miyagawa, Early detection of liver carcinogens by hepatocytes micronucleus test with juvenile/young rats, in: Proceeding of the 26th JEMS Annual Meeting, Hatano, 1997, p. 83, Abstract.
[78] A.F. McFee, P.P. Jauhar, K.W. Lowe, J.T. MacGregor, C.M. Wehr, Assay of three carcinogen/non-carcinogen chemical pairs for in vivo induction of chromosome aberrations, sister chromatid exchanges and micronuclei, Environ. Mol. Mutagen. 14 (1989) 207–220.
[79] T. Morita, N. Asano, T. Awogi, Y. Sasaki, S. Sato, H. Shimada, S. Sutou, T. Suzuki, A. Wakata, T. Sofuni, M. Hayashi, Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens. Groups 1, 2A and 2B. The summary report of the 6th collaborative study by CSGMT/JEMSMMS, Mutat. Res. 389 (1997) 3–122 [Erratum: Mutat. Res. 391 (1997) 259–267].
[80] T. Shirotori, M. Miyagawa, Induction of tissue specific micronucleated hepatocytes by liver carcinogens which are positive in in vitro chromosomal aberration test, in: Proceeding of the 27th JEMS Annual Meeting, Osaka, 1998, p. 80, Abstract.
[81] M.D. Shelby, G.L. Erexson, G.L. Hook, R.R. Tice, Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals, Environ. Mol. Mutagen. 21 (1993) 160–179.
[82] T. Morita, M. Hayashi, 1,4-Dioxane is not mutagenic in five in vitro assays and mouse peripheral blood micronucleus assay, but is in mouse liver micronucleus assay, Environ. Mol. Mutagen. 32 (1998) 269–280.
[83] J. Ashby, P.A. Lefevre, The rat-liver carcinogen N-nitrosomorpholine initiates unscheduled DNA synthesis and induces micronuclei in the rat liver in vivo, Mutat. Res. 225 (1989) 143–147.
[84] J.P. Seiler, The Mutagenicity of benzimidazole and benzimidazole derivatives. IV. Cytogenetic effects of benzimidazole derivatives in the bone marrow of the mouse and Chinese hamster, Mutat. Res. 40 (1976) 339–347.
[85] A.M. Sarrif, K.S. Bentley, L.J. Fu, R.M. O'Neil, V.L. Reynolds, R.G. Stahl, Evaluation of benomyl and carbendazim in the in vivo aneuploidy/micronucleus assay in BDF1 mouse bone marrow, Mutat. Res. 310 (1994) 143–149.
[86] R. Barale, C. Scapoli, C. Meli, D. Casini, M. Minunni, A. Marrazzini, N. Loprieno, I. Barrai, Cytogenetic effects of benzimidazoles in mouse bone marrow, Mutat. Res. 300 (1993) 15–28.
[87] A. Vanhauwaert, P. Vanparys, M. Kirsch-Volders, The in vivo gut micronucleus test detects clastogens and aneugens given by gavage, Mutagenesis 16 (2001) 39–50.
[88] N. Asano, T. Morita, Y. Watanabe, Micronucleus test with colchicine given by intraperitoneal injection and oral gavage, Mutat. Res. 223 (1989) 391–394.
[89] P. Vanparys, F. Vermeiren, M. Sysmans, R. Temmerman, The micronucleus assay as a test for the detection of aneugenic activity, Mutat. Res. 244 (1990) 95–103.
[90] I.D. Adler, U. Kliesh, P. van Hummelen, M. Kirsch-Volders, Mouse micronucleus test with known and suspect spindle poisons: results from two laboratories, Mutagenesis 6 (1991) 47–53.
[91] P. Van Hummelen, A. Deleener, P. Vanparys, M. Kirsch-Volders, Discrimination of aneuploidogens from clastogens by C-banding, DNA and area measurements of micronuclei from mouse bone marrow, Mutat. Res. 271 (1992) 13–28.
[92] R.J. Trzos, G.L. Petzold, M.N. Brunden, J.A. Swenberg, The evaluation of sixteen carcinogens in the rat using the micronucleus test, Mutat. Res. 58 (1978) 79–86.
[93] M.T. Goldberg, D.H. Blakey, W.R. Bruce, Comparison of the effects of 1,2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon, Mutat. Res. 109 (1983) 91–98.
[94] M.T. Goldberg, R.N. Schop, Assessment of 1,2-dimethylhydrazine in bone marrow micronucleus assay: variations in protocol and response, Environ. Mol. Mutagen. 17 (1991) 155–162.
[95] W. Ohyama, T. Tokumitsu, An in vivo micronucleus test using colonic epithelial cells of mice, Environ. Mutagen. Res. Commun. 17 (1996) 265–269 (in Japanese).
[96] V.S. Zhurkov, L.P. Sycheva, O. Salamatova, I.F. Vyskubenko, E.G. Feldt, N.I. Sherenesheva, Selective induction of micronuclei in the rat/mouse colon and liver by 1,2-dimethylhydrazine: a seven-tissue comparative study, Mutat. Res. 368 (1996) 115–120.
[97] A. Basler, Aneuploidy-inducing chemicals in yeast evaluated by the micronucleus test, Mutat. Res. 174 (1986) 11–13.
[98] S.L. He, R. Baker, Micronuclei in mouse skin cells following *in vivo* exposure to benzo[*a*]pyrene, 7,12-dimethylbenz[*a*] anthracene, chrysene, pyrene and urethane, Environ. Mol. Mutagen. 17 (1991) 163–168.
[99] S. Haesen, M. Timmermans, M. Kirsch-Volders, Induction of micronuclei and karyotype aberrations during *in vivo* mouse skin carcinogens, Carcinogenesis 14 (1993) 2319–2327.
[100] N. Asano, T. Hagiwara, The mouse peripheral blood micronucleus test with 2-acetylaminofluorene using the acridine orange supravital staining method, Mutat. Res. 278 (1992) 153–157.
[101] N. Asano et al. (personal communication).
[102] T. Nishikawa, T. Nakamura, A. Fukushima, Y. Takagi, Further evaluation of the skin micronucleus test: Results obtained using 10 polycyclic aromatic hydrocarbons, Mutat. Res. 588 (2005) 58–63.
[103] R.S. Baker, A.M. Bonin, A. Arlauskas, S. He, M.M. Coombs, Tumorigenicity of cyclopenta[*a*]phenanthrene derivatives and micronucleus induction in mouse skin, Carcinogenesis 13 (1992) 329–332.
[104] S. Itoh, M. Katoh, K. Furuhama, In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice, Mutat. Res. 520 (2002) 133–139.
[105] Gibson et al. (personal communication).
[106] A. Tungul, A.M. Bonin, S. He, R.S. Baker, Micronuclei induction by dichlorvos in the mouse skin, Mutagenesis 6 (1991) 405–408.

[107] H.H. Steinel, A.N. Bonin, S. He, R.S. Baker, Cytogenetic damage and tumor incidence in mouse skin after single, topical applications of 7,12-dimethylbenz[*a*]anthracene, Mutat. Res. 285 (1993) 19–26.
[108] A.O. Asita, M. Hayashi, Y. Kodama, A. Matsuoka, T. Suzuki, T. Sofuni, Micronucleated reticulocyte induction by ethylating agents in mice, Mutat. Res. 271 (1992) 29–37.
[109] R. Ciranni, R. Barale, G. Ghelardini, N. Loprieno, Benzene and the genotoxicity of its metabolites. II. The effect of the route of administration on the micronuclei and bone marrow depression in mouse bone marrow cells, Mutat. Res. 209 (1988) 23–28.
[110] M. Nakajima, M. Kikuchi, K. Saeki, Y. Miyata, M. Terada, F. Kishida, R. Yamamoto, C. Furihata, S.W. Dean, Mutagenicity of 4-nitroquinoline 1-oxide in the Muta™ Mouse, Mutat. Res. 444 (1999) 321–336.
[111] H.H. Steinel, A.M. Bonin, K. Meher-Homji, R.S. Baker, Skin carcinomas and micronucleus induction in epidermal keratinocytes following 12-o-tetradecanoylphorbol-13-acetate and mezerein treatment, Mutagenesis 7 (1992) 199–203.
[112] S.L. He, R.S. Baker, Initiating carcinogen, triethylenemelamine, induces micronuclei in skin target cells, Environ. Mol. Mutagen. 14 (1989) 1–5.
[113] J. Maki-Paakkanen, M. Hayashi, T. Suzuki, H. Tanabe, M. Honma, T. Sofuni, Analysis by fluorescence in situ hybridization with a mouse gamma satellite DNA probe of isolated micronuclei induced in mice by two clastogens and two spindle poisons, Mutagenesis 10 (1995) 513–516.
[114] A. Russo, G. Gabbani, B. Simoncini, Weak genotoxicity of acrylamide on premeiotic, somatic cells of the mouse, Mutat. Res. 309 (1994) 263–272.
[115] J. Lähdetie, A. Keisi, A. Suutari, J. Toppari, Etoposide (VP-16) is a potent inducer of micronuclei in male rat meiosis: spermatid micronucleus test and DNA flow cytometry after etoposide treatment, Environ. Mol. Mutagen. 24 (1994) 192–202.
[116] Y. Xiao, A.D. Tates, Increased frequencies of micronuclei in early spermatids of rats following exposure of young primary spermatocytes to acrylamide, Mutat. Res. 309 (1994) 245–254.
[117] A.M. Tommasi, S. de Conti, M. Dobrzynska, A. Russo, Evaluation and characterization of micronuclei in early spermatids of mice exposed to 1,3-butadiene, Mutat. Res. 397 (1998) 45–54.
[118] Y. Xiao, A.D. Tates, Clastogenic effects of 1,3-butadiene and its metabolites 1,2-epoxybutene and 1,2,3,4-dipexybutane in splenocytes and germ cells of rats and mice in vivo, Environ. Mol. Mutagen. 26 (1995) 97–108.
[119] J. Lähdetie, K. Peltonen, T. Sjöblom, Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: induction of spermatid micronuclei by butadiene mono-, di-, dioloepoxides in vivo, Environ. Mol. Mutagen. 29 (1997) 230–239.
[120] F. Matsuo, M. Nakai, T. Nasu, The fungicide carbendazim induces meiotic micronuclei in the spermatids of the rat testis, J. Vet. Med. Sci. 61 (1999) 573–576.
[121] J.W. Allen, B.W. Collins, P.A. Evansky, Spermatid micronucleus analyses of trichloroethylene, chloral hydrate effects in mice, Mutat. Res. 323 (1994) 81–88.
[122] E.V. Nutley, A.C. Tcheong, J.W. Allen, B.W. Collins, M. Ma, X. Lowe, J.B. Bishop, D.H. Moore, A.J. Wyrobek, Micronuclei induced in round spermatids of mice after stem-cell treatment with chloral hydrate: evaluations with centromeric DNA probes and Kinetochore antibodies, Environ. Mol. Mutagen. 28 (1996) 80–89.
[123] A. Russo, C. Nogara, L. Renzi, A.M. Tommasi, Micronucleus induction in germ and somatic cells of the mouse after exposure to the butadiene metabolites diepoxybutane and epoxybutene, Mutat. Res. 390 (1997) 129–139.
[124] M. Kallio, J. Lähdetie, Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest, induction of aneuploidy, Environ. Mol. Mutagen. 29 (1997) 16–27.
[125] J.W. Allen, B.W. Collins, A. Lori, A.J. Afshari, M.H. George, A.B. DeAngelo, J.C. Fuscoe, Erythrocyte and spermatid micronucleus analyses in mice chronically exposed to potassium bromate in drinking water, Environ. Mol. Mutagen. 36 (2000) 250–253.
[126] C. Tiveron, A. Russo, B. Bassani, F. Pacchierotti, Genotoxicity of trophosphamide in mouse germ cells: assessment of micronuclei in spermatids and chromosome aberrations in one-cell zygotes, Mutagenesis 11 (1996) 125–130.
[127] A. West, A. Suutari, J. Lähdetie, Detection of germ cell mutagenicity of trophosphamide by the spermatid micronucleus test in the rat, Mutagenesis 10 (1995) 287–290.
[128] E.V. Nutley, A.C. Tcheong, J.W. Allen, B.W. Collins, M. Ma, X.R. Lowe, J.B. Bishop, D.H. Moore II, A.J. Wyrobek, Micronuclei induced in round spermatids of mice after stem-cell treatment with chloral hydrate: evaluations with centromeric DNA probes and kinetochore antibodies, Environ. Mol. Mutagen. 28 (1996) 80–89.
[129] R.J. Cole, N. Taylor, J. Cole, C.F. Arlett, Short-term tests for transplacentally active carcinogens. I. Micronucleus formation in fetal and maternal mouse erythroblasts, Mutat. Res. 80 (1981) 141–157.
[130] R.J. Cole, N. Taylor, J. Cole, A. Henderson, C.F. Arlett, Short-term tests for transplacentally active carcinogens. Sensitivity of the transplacental micronucleus test to diethylnitrosamine, Mutat. Res. 104 (1982) 167–171.
[131] R.J. Cole, J. Cole, L. Henderson, N. Taylor, C.F. Arlett, T. Regan, Short-term tests for transplacentally active carcinogens. A comparison of sister-chromatid exchange and the micronucleus test in mouse foetal liver erythroblasts, Mutat. Res. 113 (1983) 61–75.
[132] Y. Kikuchi, K.I. Yamamoto, Y. Nakajima, Relevance of the mouse fetal liver micronucleus test to embryotoxicity studies, Teratology 28 (1983) 33A.
[133] K.I. Yamamoto, Y. Kikuchi, Induction of micronuclei in mouse fetal liver after exposure in utero to *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, Mutat. Res. 128 (1984) 173–179.
[134] E. Giavini, L. Bonanomi, G. Ornaghi, Developmental toxicity during the preimplantation period: embryotoxicity and clastogenic effects of chlorambucil in the rat, Teratogen. Carcinogen. Mutagen. 4 (1984) 341–348.
[135] T. Karube, Y. Odagiri, K. Takemoto, S. Watanabe, Analyses of transplacentally induced sister chromatid exchanges and micronuclei in mouse fetal liver cells following maternal exposure to cigarette smoke, Cancer Res. 49 (1989) 3550–3552.
[136] L. Müller, Micronucleus induction in mouse and rat fetuses treated transplacentally during histogenesis with mitomycin C and 7,12-dimethylbenz[*a*]anthracene, Teratogen. Carcinogen. Mutagen. 8 (1988) 303–313.
[137] M.Y. Wang, L.J.W. Lu, Differential effect of gestation stage on benzo[*a*]pyrene-induced micronucleus formation and/or covalent DNA modification in mice, Cancer Res. 50 (1990) 2146–2151.
[138] L.J.W. Lu, J.R. Baxter, M.Y. Wang, B.L. Harper, F. Tasaka, K. Kohda, Induction of covalent DNA modifications and micronu-

cleated erythrocytes by 4-nitroquinone 1-oxide in adult and fetal mice, Cancer Res. 50 (1990) 6192–6198.
[139] H. Ning, N.Y. Kado, P.A. Kuzmicky, D.P. Hsieh, Benzene-induced micronuclei formation in mouse fetal liver blood, peripheral blood, and maternal bone marrow cells, Environ. Mol. Mutagen. 18 (1991) 1–5.
[140] B.J. Sanderson, A.M. Clark, Micronuclei in adult and foetal mice exposed in vivo to heliotrine, urethane, monocrotaline and benzidine, Mutat. Res. 285 (1993) 27–33.
[141] J.T. MacGregor, P.R. Henika, L. Whitehand, C.M. Wehr, The fetal blood erythrocyte micronucleus assay: classification of RNA-positive erythrocytes into two age populations by RNA aggregation state, Mutagenesis 4 (1989) 190–199.
[142] K. Abraham, Inhibitory effects of coffee on transplacental genotoxicity in mice, Mutat. Res. 347 (1995) 45–52.
[143] N. Titenko-Holland, T. Ahlborn, X. Lowe, N. Shang, M.T. Smith, A.J. Wyrobek, Micronuclei and developmental abnormalities in 4-day mouse embryos after paternal treatment with acrylamide, Environ. Mol. Mutagen. 31 (1998) 206–217.
[144] Y. Tian, H. Ishikawa, T. Yamauchi, Analysis of cytogenetic and developmental effects on pre-implantation, mid-gestation and near-term mouse embryos after treatment with trichlorfon during zygote stage, Mutat. Res. 471 (2000) 37–44.
[145] Y. Tian, T. Yamauchi, Micronucleus formation in 3-day mouse embryos associated with maternal exposure to chlorpyrifos during the early preinplantation period, Reprod. Toxicol. 17 (2003) 401–405.

Congenital Anomalies 2005; **45**, 146–153

ORIGINAL ARTICLE

Elevated susceptibility of newborn as compared with young rats to 2-*tert*-butylphenol and 2,4-di-*tert*-butylphenol toxicity

Mutsuko Hirata-Koizumi[1], Masao Hamamura[2], Hiromi Furukawa[2], Naemi Fukuda[3], Yoshihiko Ito[3], Yumi Wako[4], Kotaro Yamashita[4], Mika Takahashi[1], Eiichi Kamata[1], Makoto Ema[1], and Ryuichi Hasegawa[1]

[1]National Institute of Health Sciences, Setagaya-ku, Tokyo; [2]Panapharm Laboratories, Uto-shi, Kumamoto; [3]Research Institute for Animal Science in Biochemistry and Toxicology, Sagamihara-shi, Kanagawa; and [4]Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd, Ibaraki, Japan

ABSTRACT **In order to determine the susceptibility of newborn rats to 2-*tert*-butylphenol (2TBP) and 2,4-di-*tert*-butylphenol (DTBP) toxicity, studies were conducted with oral administration from postnatal days (PND) 4 to 21 and the findings were compared with results for young rats exposed from 5 or 6 weeks of age for 28 days. In the newborn rats, specific effects on physical and sexual development and reflex ontogeny were not observed. While there were no clear differences in toxicological profiles between newborn and young rats, the no-observed-adverse-effect levels (NOAELs) differed markedly. For 2TBP, clinical signs such as ataxic gait, decrease in locomotor activity and effects on liver, such as increase in organ weight, were observed and the NOAELs were concluded to be 20 and 100 mg/kg/day in newborn and young rats, respectively. Based on hepatic and renal toxicity (histopathological changes and increase in organ weight with blood biochemical changes), the respective NOAELs for DTBP were concluded to be 5 and 20 mg/kg/day. Therefore, the susceptibility of newborn rats to 2TBP and DTBP was found to be 4–5 times higher than that of young rats.**

Key Words: 2, 4-di-*tert*-butylphenol, 2-*tert*-butylphenol, susceptibility of newborn rats

INTRODUCTION

Protection of humans against disease and injury caused by chemicals in the environment is the ultimate goal of risk assessment and risk management (Landrigan *et al.* 2004). However, the focus has long been solely on adult exposure and toxicity and the fetus via maternal transfer, with little consideration given to early childhood. In the past decade, stimulated especially by the 1993 US National Research Council (NRC) report *Pesticides in the Diets of Infants and Children* (NAS 1993), recognition that special consideration is required for children in risk assessment has grown. The NRC report noted that 'children are not little adults', because of their unique patterns of exposures to environmental hazards and their particular vulnerability.

For the susceptibility of children to environmental chemicals, the early postnatal period (the suckling period) is of particular note. During this period, the infant could be exposed to various chemicals not only through mothers' milk, but also directly, by having chemical-contaminated baby food, mouthing toys or household materials, and so on; however, current risk assessment gives no consideration to toxic effects resulting from direct exposure to chemicals. An approach that adequately takes into account the susceptibility of infancy is urgently required. However, because there is no standard testing protocol intended for direct exposure of preweaning animals (newborn animals) to chemicals, and toxicity studies using newborn animals are complicated by practical difficulties regarding grouping, direct dosing, and general and functional observation, there is only limited information on susceptibility of the newborn at the present.

We therefore have established a new protocol for repeated dose toxicity studies using newborn rats (newborn rat studies) (Koizumi *et al.* 2001) for systematic application. Results have been compared with those of 28-day repeated dose toxicity studies using young rats (young rat studies) to provide a basis of analyzing susceptibility. Since young rat studies are routinely conducted as one of a battery of minimum toxicity tests and data are stored for many chemicals, comparative analyzes should provide important information for considering effects of direct exposure to chemicals during the suckling period.

We have already reported analytical results for eight chemicals (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol, 1,3-dibromopropane, 1,1,2,2-tetrabromoethane, 2,4,6-trinitrophenol, and tetrabromobisphenol A) (Koizumi *et al.* 2001, 2002, 2003; Fukuda *et al.* 2004; Takahashi *et al.* 2004; Hirata-Koizumi *et al.* 2005). The susceptibility of newborn rats to the toxicity of the first four agents was four times higher than that of their young counterparts at a maximum. For 1,3-dibromopropane and 1,1,2,2-tetrabromoethane, while the doses causing clear toxicity were lower in newborn rats, doses at which toxic signs began to appear were paradoxically higher in the newborn case. These six chemicals had no impact on development in the newborn period and showed similar toxicity profiles in both age groups. For the other two chemicals, there were marked differences in toxicity profile between the newborn and young rats. Especially, in the case of tetrabromobisphenol A, a specific rather than enhanced renal toxicity was observed in newborn case.

In the present investigation, two *tert*-butylphenols, 2-*tert*-butylphenol (2TBP), and 2,4-di-*tert*-butylphenol (DTBP), were chosen for comparative toxicity analysis. 2TBP has been used in the production of agricultural chemicals, aroma chemicals, and resins (New Chemical Index 2001), and DTBP in the production of antioxidants and ultraviolet absorbers (Chemical Products' Handbook 2004). For either chemical, there is no available toxicity information on human. Regarding toxicity to experimental animals, results from young rat studies of both chemicals are available in

Correspondence: Mutsuko Hirata-Koizumi, BSc, Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Email: mkoizumi@nihs.go.jp

Received June 17, 2005; revised and accepted September 2, 2005.

Toxicity Testing Reports of Environmental Chemicals of the Japanese government (MHLW 2001a, 2001b), but no other data have been reported regarding repeated dose toxicity. Since the young rats were only evaluated for toxicity profiles and no-observed-effect levels, we re-evaluated the results for a more practical evaluation index, the no-observed-adverse-effect level (NOAEL), which could serve as the basis for determining tolerable daily intake (TDI) or acceptable daily intake (ADI) for risk assessment, and conducted comparative analyzes with newborn rats.

MATERIALS

2-*tert*-Butylphenol (2TBP, CAS no. 88-18-6, purity: 99.97%) and 2,4-di-*tert*-butylphenol (DTBP, CAS no. 96-76-4, purity: 99.67%), obtained from Dainippon Ink and Chemicals, Incorporated (Tokyo, Japan), were dissolved in olive oil and corn oil, respectively. The test solutions were prepared once a week as stability for eight days had been confirmed. All other reagents used in this study were specific purity grade.

METHODS

All studies were performed under Good Laboratory Practice conditions and in accordance with 'Guidance for Animal Care and Use' of Panapharm Laboratories Co., Ltd, Research Institute for Animal Science in Biochemistry and Toxicology, or Mitsubishi Chemical Safety Institute Ltd.

Animals

In the newborn rat studies of 2TBP and DTBP, pregnant SPF Sprague-Dawley rats [Crj:CD(SD)IGS] were purchased at gestation days 13–15 from Charles River Japan Inc. (Yokohama, Japan), and allowed to deliver spontaneously. All newborn were separated from dams at postnatal day (PND) 3 (the date of birth was defined as PND 0), and pooled according to sex. At the same time, 12 foster mothers were selected among dams, based on the nursing condition. Each foster mother suckled four male and four female newborn, assigned to each of the four dose groups, including the controls, up to weaning on PND 21 (termination of dosing). After weaning, the animals of the recovery-maintenance group (see Study Design) were individually maintained for nine weeks.

In the young rat studies, 4–5 week-old males and females of the same strain were obtained from the same supplier as for the newborn rat studies, and used at ages of 5–6 weeks after acclimation.

All animals were maintained in an environmentally controlled room at 20–26°C with a relative humidity of 40–70%, a ventilation rate of more than ten times per hour, and a 12:12 h light/dark cycle. They were allowed free access to a basal diet (MF: Oriental Yeast Co. Ltd, Tokyo, Japan, or LABO MR Stock: Nihon Nosan Kogyo Inc., Yokohama, Japan) and water (sterile tap water or well water treated with sodium hypochlorite) throughout.

Study design

1. 18-day repeated dose toxicity study in newborn rats (newborn rat study)

Newborn rats (12/sex/dose) were administered the test substances by gastric intubation on PNDs 4–21. On PND 22, six males and six females in each treated group were sacrificed for autopsy (the scheduled-sacrifice group). The remaining animals in all groups (6 rats/sex/dose) were maintained for nine weeks without chemical treatment and then sacrificed at 12 weeks of age (the recovery-maintenance group).

Based on the results of dose-finding studies conducted prior to the main study, the dose, which would show clear toxicity, was selected as the top dose, that without potentially toxic effects as the lowest dose, and the medium dose was set between them. In the dose-finding study for 2TBP (oral administration from PNDs 4–21), some clinical signs and suppressed body weight gain were observed at 200 mg/kg and an increase in relative liver weight at 60 mg/kg and more. For DBTP (oral administration from PNDs 4–17), all of the four males and four females died at 500 mg/kg, and the death of one of the four males, an increase in serum total cholesterol and phospholipid, and increase in relative liver weight were noted in the 100 mg/kg group. Therefore, the doses were set at 0, 20, 60, or 200 mg/kg/day for 2TBP and at 0, 5, 40, or 300 mg/kg/day for DTBP.

During the study, the rats' general condition was observed at least once a day (details of clinical signs noted in this study are described in 'Glossary of terms for toxicity testing' [NIHS 1994]). Body weight and food consumption (only the recovery-maintenance period) was examined once or more a week. As developmental parameters, fur appearance, incisor eruption, pinna detachment and eye opening were assessed for physical development, and testes descent or preputial separation and vaginal opening for sexual development (OECD 2004). In addition, reflex ontogeny, such as visual placing reflex, and surface and mid-air righting reflexes, were also examined (Adams 1986; Jensh & Brent 1988). Urinalysis (color, occult blood, pH, protein, glucose, ketone bodies, bilirubin, urobilinogen, sediment, specific gravity, and volume of the urine) was conducted in the last week of the recovery-maintenance period.

At PNDs 22 and 85, blood was collected from the abdominal aorta under ether anesthesia (for 2TBP) or from the postcaval vein under pentobarbital sodium anesthesia (for DTBP) after overnight starvation for the scheduled-sacrifice and recovery-maintenance groups, respectively. One portion was treated with EDTA-2K and examined for hematological parameters, such as the red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count, platelet count, reticulocyte count and differential leukocyte count. In the recovery-maintenance group, part of the blood was treated with 3.8% sodium citrate, and blood clotting parameters such as prothrombin time (PT) and activated partial thromboplastin time (APTT) were examined. Serum from the remaining portions of blood for both the scheduled-sacrifice and recovery-maintenance groups were analyzed for blood biochemistry (total protein, albumin, albumin-globulin ratio [A/G ratio], glucose, total cholesterol, triglycerides, phospholipid, total bilirubin, urea nitrogen [BUN], creatinine, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyl transpeptidase [γ-GTP], calcium, inorganic phosphorus, sodium, potassium, and chlorine). Following collection of blood, all animals were sacrificed by exsanguination, and all organs and tissues were macroscopically examined. Then, the brain, pituitary gland, thymus, thyroids, heart, lungs, liver, spleen, kidneys, adrenals, testes, epididymides, and ovaries were removed and weighed. Histopathological examination was conducted for the control and the highest dose groups. The above-listed organs were fixed in 10% buffered formalin-phosphate (following Bouin's fixation for testes and epididymides), and paraffin sections were routinely prepared and stained with Hematoxylin-Eosin for microscopy. For other groups, organs with macroscopically abnormal findings or in which chemical-related effects were evident on microscopic examination for the highest dose group, were similarly investigated.

2. 28-day repeated dose toxicity study in young rats (young rat study)

Five to six week old rats were given the test substances by gastric intubation daily for 28 days and sacrificed following the last treatment (the scheduled-sacrifice group). Recovery groups were maintained for two weeks without chemical treatment and sacrificed at 11 or 12 weeks of age. The number of animals was six for each sex/dose for both scheduled-sacrificed and recovery cases.

The doses were selected in the same way as the newborn rat studies. In the 12-day dose-finding study for 2TBP, ataxic gait was observed at 300 mg/kg and more, and increase in relative liver and kidney weight at 500 mg/kg. For DTBP, with 14-day administration, the death of one of the four females, various changes in some blood biochemical parameters, increase in relative liver weights and light gray macules on kidneys were found at 500 mg/kg. Increase in serum phospholipid and relative liver weights were also demonstrated in the 100 mg/kg group. Based on the results, the doses were determined at 0, 4, 20, 100, or 500 mg/kg/day for 2TBP and at 0, 5, 20, 75, or 300 mg/kg/day for DTBP. Recovery groups were set at 0, 100, 500 mg/kg/day for 2TBP and 0, 300 mg/kg/day for DTBP.

During the study, rats were examined for general condition, body weight, food consumption, urinalysis, hematology and blood biochemistry, necropsy findings, organ weights, and histopathological findings in compliance with the Test Guideline in the Japanese Chemical Control Act (Official Name: Law Concerning the Examination and Regulation of Manufacture, etc. of Chemical Substances).

Statistical analysis

Data for body weights, food consumption, urinalysis findings (except for the results of qualitative analysis), hematological, blood biochemical findings (except for differential leukocyte count), and organ weights were analyzed by the Bartlett's test (Bartlett 1937) for homogeneity of distribution. When homogeneity was recognized, Dunnett's test (Dunnett 1964) was conducted for comparison between control and individual treatment groups ($P < 0.01$ or 0.05). If not homogeneous or for qualitative urinalysis data and differential leukocyte count, the data were analyzed using Steel's multiple comparison tests (Steel 1959), or tests of the Dunnett type (Hollander & Wolfe 1973) ($P < 0.01$ or 0.05). For reflex ontogeny, and physical and sexual development parameters in the newborn rat studies, the χ^2-test (Fisher 1922) was conducted ($P < 0.01$ or 0.05).

RESULTS

2-*tert*-butylphenol (2TBP)

Newborn rat study

Various clinical signs such as decrease in locomotor activity, ataxic gait, deep respiration, and muscle weakness were observed throughout the dosing period in the 200 mg/kg group, as shown in Table 1. With 60 mg/kg, transient decrease in locomotor activity was noted on the first dosing day limited to only one of 12 males. Body weights were lowered by 8–17% from dosing day 7 through to the end of the dosing period in males and to recovery-maintenance day 14 in females given 200 mg/kg. At the scheduled sacrifice, there were no hematological changes at any dose, but blood biochemical examination of the 200 mg/kg group showed increases in γ-GTP in both sexes and total protein in males. In addition, significant increase in relative liver weights was noted in 9% of the females in the 60 mg/kg group and in 21–23% of both males and females in the 200 mg/kg group. On histopathological examination, slight hypertrophy of centrilobular hepatocytes was found in one female of the 60 mg/kg group, and in four males and three females from the 200 mg/kg group. During the recovery-maintenance period, no clinical signs were observed and the lowered body weights showed a tendency for recovery. In parameters for physical and sexual development and reflex ontogeny, no definitive changes were detected. At the end of the recovery-maintenance period, no chemical-related changes, also in urinalysis data, were found in any dose group.

The results of the newborn rat study of 2TBP are summarized in Table 2. Since clinical signs and histopathological changes in the liver were observed in the 60 mg/kg group, the NOAEL was concluded to be 20 mg/kg/day.

Young rat study

Ataxic gait were observed sporadically during the dosing period in nine males and 12 females, and decrease in locomotor activity in two females from the 500 mg/kg group. During the dosing period, there were no changes in body weight, food consumption, and urinalysis data. At the scheduled sacrifice, hematological and blood biochemical examination also showed no changes. Eighteen to 19% increases were found in relative liver weights of both sexes receiving 500 mg/kg, but no histopathological changes in liver were observed at any dose. No chemical-related changes were noted during and at the end of the recovery period.

Table 1 Clinical signs observed during the dosing period in the newborn rat study of 2-*tert*-butylphenol

	Dose (mg/kg/day)			
	0	20	60	200
No. animals (Male/Female)	12/12	12/12	12/12	12/12
No. animals with clinical signs				
Decrease in locomotor activity	0/0	0/0	1†/0	12/12
Ataxic gait	0/0	0/0	0/0	4/6
Deep respiration	0/0	0/0	0/0	12/12
Tremors	0/0	0/0	0/0	2/4
Muscle weakness	0/0	0/0	0/0	12/12
Emaciation	0/0	0/0	0/0	2/2
Pale skin	0/0	0/0	0/0	4/2

†Observed only on the first dosing day.

Table 2 Summary of the results of the newborn and young rat study of 2-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	20	60	200	
Clinical signs	–	M: Decrease in locomotor activity	Various†	
Body weight changes	–	–	8–17%↓	
Blood biochemical changes	–	–	GTP↑, M: TP↑	
Changes in relative organ weights	–	F: Liver 9%↑	Liver 21–23%↑	
Histopathological findings in liver				
– Slight centrilobular hypertrophy of hepatocytes	–	M: 0/6, F: 1/6	M: 4/6, F: 3/6	
Young rat study				
Dose (mg/kg/day)	4	20	100	500
Clinical signs	–	–	–	Ataxic gait F: Decrease in locomotor activity
Body weight changes	–	–	–	–
Blood biochemical changes	–	–	–	–
Changes in relative organ weights	–	–	–	Liver 18–19%↑
Histopathological findings	n.d.	n.d.	n.d.	–

Statistically significant increases ($P < 0.05$) in body weights, blood biochemical parameters and relative organ weights are shown as ↑, while decreases are shown as ↓. Data on histopathological findings are given as no. of animals with the findings/no. of animals examined, according to sex. Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. No chemical-related changes were observed in developmental parameters (conducted only in newborn rat study), urinalysis (only in young rat study), and hematological parameters. †Decrease in locomotor activity, ataxic gait, deep respiration, tremors, muscle weakness, emaciation, and pale skin were observed, as shown in Table 1. GTP, γ-GTP; TP, total protein; –, no change; n.d., not determined.

A summary of the results of the young rat study of 2TBP is given in Table 2. The NOAEL was concluded to be 100 mg/kg/day, at which no changes were observed.

2,4-di-*tert*-butylphenol (DTBP)

Newborn rat study

Two males and one female of the 300 mg/kg group were found dead on dosing days 3, 4, and 7. In this group, decrease in locomotor activity (12 males and 12 females), bradypnea (10 males and 10 females), and hypothermia (one male) were observed from the first dosing day, but then the incidence decreased, with disappearance after dosing day 7. Body weights of the 300 mg/kg group were lowered by 15–25% in males and by 9–20% in females during the dosing period, compared with the control values. There were no definitive changes in parameters for physical development and reflex ontogeny in any dose group. At the scheduled sacrifice, blood biochemical examination showed an increase in total bilirubin and a decrease in the A/G ratio in both sexes, an increase in γ-GTP in males, and an increase in total protein and BUN in females of the 300 mg/kg group. In the 300 mg/kg group, there was a 39–51% increase in relative liver weights, a 37–41% increase in relative kidney weights in both sexes, and a 24% decrease in relative spleen weights in males. In the 40 mg/kg group, 14% increases in relative weight of liver were found in females. On histopathological examination, various changes were observed in livers and kidneys in the 300 mg/kg group, as shown in Table 3. Furthermore, periportal fatty degeneration of hepatocytes was evident in one female given 40 mg/kg, and basophilic tubules in kidneys in one animal of each sex receiving 40 mg/kg and one control group male. Regarding parameters of sexual development, a slight delay in preputial separation was noted in the 300 mg/kg group (the incidences were 0/5, compared with 2/6 in the control group at PND 42 [recovery-maintenance day 21]; 0/5, 3/6 at PND 43; 2/5, 5/6 at PND 44; 2/5, 6/6 at PND 46; 4/5, 6/6 at PND 47; and 5/5, 6/6 at PND 48). During this observation period, body weights were lowered by approximately 10% in males given 300 mg/kg than control levels, which was not statistically significant. In the last week of the recovery-maintenance period, there were no chemical-related changes on urinalysis in any dose group. At the end of the recovery period, changes noted in the scheduled-sacrifice group were not observed except for histopathological changes in the kidneys, significant in the 300 mg/kg group (Table 3).

A summary of the results of the newborn rat study of DTBP is shown in Table 4. Since fatty degeneration of hepatocytes and increase in liver weight were demonstrated at 40 mg/kg, the NOAEL was concluded to be 5 mg/kg/day.

Young rat study

No chemical-related changes were found in general condition, body weight, and food consumption at any dose. On urinalysis at the fourth week of dosing, an increase in urine volume, and a decrease in specific gravity and osmotic pressure were noted in both sexes of the 300 mg/kg group. At the scheduled sacrifice, hematological examination showed a decrease in hemoglobin and hematocrit, an increase in segmented neutrophils in females, and prolongation of PT and APTT in males at 300 mg/kg. On blood biochemical examination, there was an increase in total bilirubin in males given 300 mg/kg, and an increase in total cholesterol and phospholipid in females given 75 mg/kg and above. For organ weights, there were

Table 3 Histopathological findings for the newborn rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group				Recovery-maintenance group†	
Dose (mg/kg/day)	Grade	0	5	40	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	5/6	6/6	5/5
Liver							
– Fatty degeneration of periportal hepatocytes	+	0/0	0/0	0/1	0/0	0/0	0/0
	++	0/0	0/0	0/0	3/4	0/0	0/0
	+++	0/0	0/0	0/0	2/2	0/0	0/0
Kidneys							
– Basophilic tubules	+	1/0	n.d.	1/1	4/4	0/0	3/0
– Granular casts	+	0/0	n.d.	0/0	4/2	0/0	0/0
– Cystic dilatation of collecting tubules	+	0/0	n.d.	0/0	0/0	0/0	5/4
	++	0/0	n.d.	0/0	3/4	0/0	0/0
	+++	0/0	n.d.	0/0	2/2	0/0	0/0
– Cellular infiltration of neutrophils	+	0/0	n.d.	0/0	2/1	0/0	1/0
	++	0/0	n.d.	0/0	1/1	0/0	1/0
	+++	0/0	n.d.	0/0	1/1	0/0	0/0

†No histopathological examination was conducted at 5 and 40 mg/kg in the recovery-maintenance group. +, mild; ++, moderate; +++, marked; n.d., not determined.

increases in relative liver weights by 40–43% in both sexes given 300 mg/kg, and by 13% in females receiving 75 mg/kg. On histopathological examination, mild to marked changes in livers and kidneys were observed in both sexes from the 300 mg/kg group, as shown in Table 5. At the end of the recovery period, the increase in total cholesterol and phospholipid and renal histopathological changes observed in the scheduled-sacrifice group remained significant in the highest-dose group (Table 5).

The results of the young rat study are summarized in Table 4. Based on increase in the relative liver weights with some changes in blood biochemical parameters in females given 75 mg/kg, the NOAEL was concluded to be 20 mg/kg/day.

DISCUSSION

During development, many rapid and complex biological changes occur, which can have profound consequences on sensitivity to the effects of exogenous chemicals (Scheuplein *et al.* 2002). Although the neonatal body at birth is reasonably well prepared for the abrupt changes associated with parturition, and most functional systems possess a significant portion of their adult capacity (Dourson *et al.* 2002), it is known that the various functions remain immature in early postnatal period and that some organs and tissues, especially in the nervous, immune and reproductive systems, continue to develop after birth (NAS 1993). Therefore, it is important to evaluate toxic effects by exposure to chemicals during the early postnatal period as well as the fetal period for comprehensive risk assessment. However, economic issues and lack of human resources, arising from practical difficulties regarding protocols, have hindered routine implementation of toxicity studies using newborn animals. Our series of comparative analyzes on susceptibility of the newborn are therefore of particular importance for risk assessment.

In the present study on 2TBP and DTBP, there were no clear differences in toxicity profiles between the newborn and young rats in either case. For 2TBP, clinical signs such as a decrease in locomotor activity and ataxic gait, and effects on liver such as an increase in organ weight were observed. In the DTBP case, hepatic and renal toxicity (histopathological changes, increase in organ weight, etc.) were noted. As a characteristic effect of DTBP on male sexual development, slight delay in preputial separation was also observed in the newborn rat study. Preputial separation, an androgen-dependent process which is an early marker of puberty, represents a reliable non-invasive indicator of chemical-induced perturbation of male pubertal development in the rat (Gaytan *et al.* 1988). However, it is known that decreased body weights can result in non-specific delay in puberty (Ashby & Lefevre 2000). Since DTBP lowered body weights in the period of observation of preputial separation and there were no DTBP-related changes in weights or histopathology of the testes and epididymides, well known to be essentially androgen-dependent, no specific effect on male sexual development could be concluded in the present study. As for NOAELs of both chemicals, clear differences were observed between newborn and young rats, with values of 20 and 5 mg/kg/day in newborn rats, and 100 and 20 mg/kg/day in young rats for 2TBP and DTBP, respectively. Therefore, the susceptibility was four- to five-fold higher in newborn than in young rats.

Our previous analysis of 1,3-dibromopropane and 1,1,2,2-tetrabromoethane (Hirata-Koizumi *et al.* 2005) showed dose–response curves to be very different between newborn and young rats. The same was recently reported for the widely used organophosphorus insecticide, chlorpyrifos (Zheng *et al.* 2000), as well as pyrethroid insecticides (Shafer *et al.* 2005). These data showed the importance of estimating unequivocally toxic levels (UETLs), defined for our comparative toxicity analysis as equivalent toxic doses inducing clear toxicity, including death, clinical toxic signs,

Table 4 Summary of the results of the newborn and young rat study of 2,4-di-*tert*-butylphenol

Newborn rat study				
Dose (mg/kg/day)	5	40	300	
Death	–	–	M: 2/12, F: 1/12	
Clinical signs	–	–	Decrease in locomotor activity bradypnea, hypothermia	
Body weight changes	–	–	9–25%↓	
Urinalysis	n.d.	n.d.	n.d.	
Hematological changes	–	–	–	
Blood biochemical changes	–	–	Various†	
Changes in relative organ weights	–	F: Liver 14%↑	Liver 39–51%↑, Kidney 37–41%↑ M: Spleen 24%↓	
Histopathological findings	–	F: Fatty degeneration in liver	Various changes in liver and kidney‡	
Developmental parameters	–	–	Slight delay in preputial separation	
Young rat study				
Dose (mg/kg/day)	5	20	75	300
Death	–	–	–	–
Clinical signs	–	–	–	–
Body weight changes	–	–	–	–
Urinalysis	–	–	–	UV↑ SG↓ OP↓
Hematological changes	–	–	–	Various§
Blood biochemical changes	–	–	F: Tcho↑ Pho↑	M: TB↑ F: Tcho↑ Pho↑
Changes in relative organ weights	–	–	F: Liver 13%↑	Liver 40–43%↑
Histopathological findings	n.d.	n.d.	–	Various changes in liver and kidney¶

Data on death are shown as no. of dead animals/no. of animals examined, according to sex. Statistically significant increases ($P < 0.05$) in body weights, urinalysis and blood biochemical parameters, and relative organ weights are shown as ↑, while decreases are shown as ↓. Changes observed only in males or females are shown as 'M' or 'F', respectively, while neither 'M' nor 'F' is mentioned in the case of changes noted in both sexes. †Increase in total bilirubin and decrease in the A/G ratio in both sexes, increase in γ-GTP in males, and increase in total protein and BUN in females were noted. ‡Various changes were observed as shown in Table 3. §Various hematological changes were noted such as decrease in hemoglobin and hematocrit and increase in segmented neutrophils in females and prolongation of PT and APTT in males. ¶Various changes were observed as shown in Table 5. OP: osmotic pressure; Pho: phospholipid; SG: specific gravity; TB: total bilirubin; Tcho: total cholesterol; UV: urine volume; –: no change; n.d.: not determined.

or critical histopathological damage (Koizumi *et al.* 2001). We here tried to apply this UETL approach to the present study. For 2TBP, clinical signs such as decrease in locomotor activity and ataxic gait were noted in most of the animals given 200 mg/kg (newborn rats) and 500 mg/kg (young rats) (Table 2). Furthermore, a 8–17% lowering of body weight was observed at 200 mg/kg in newborn rats, but not in the young rat study. Therefore, equivalent toxic effects to these observed at 500 mg/kg in young rats might be expected to appear at 100–150 mg/kg in newborn animals. The UETLs were concluded to be 100–150 and 500 mg/kg/day in newborn and young rats, respectively. In the case of DTBP, clear toxicity was observed at the top dose of 300 mg/kg in both newborn and young rat studies (Table 4), but the level of severity was very different, for example, deaths were only noted in the newborn cases. It was considered difficult to estimate the UETLs from the results of main studies only. However, the most critical endpoint for toxicity, mortality, was also noted at 100 mg/kg and more, and 500 mg/kg, in the dose-finding studies of newborn and young rats, respectively. Therefore, it would be possible to estimate the appropriate UETLs as the minimum lethal dose by taking the results of the dose-finding studies into consideration. The UETLs were concluded to be 100 mg/kg/day for the newborn, and 500 mg/kg/day for young rats, at which one out of eight rats was found dead in both cases. These analyzes of UETLs, considering equivalence in toxic degree, showed 3.3–5.0 times higher susceptibility of newborn rats to 2TBP and DTBP than young rats, consistent with our analytical results for NOAELs.

Higher susceptibility of newborn rats was also demonstrated in our previous analyzes of five phenols (4-nitrophenol, 2,4-dinitrophenol, 3-aminophenol, 3-methylphenol and 2,4,6-trinitrophenol) (Koizumi *et al.* 2001, 2002, 2003; Takahashi *et al.* 2004), considered mainly due to their poor metabolic and excretory capacity (Horster 1977; Cresteil *et al.* 1986). It has actually been reported that UDP-glucuronyltransferase and sulfotransferase activities, when 4-nitrophenol is used as the substrate, are lower in microsomes prepared from livers of newborn rats, and that the elimination rate of 2,4-dinitrophenol from serum of newborn rabbits is markedly slower than in young adults (Gehring & Buerge 1969; Matsui & Watanabe 1982). Unfortunately, there is no information on the toxicity mechanism and toxicokinetics of both 2TBP

Table 5 Histopathological findings for the young rat study of 2,4-di-*tert*-butylphenol

		Scheduled-sacrifice group†			Recovery group	
Dose (mg/kg/day)	Grade	0	75	300	0	300
No. of animals examined (Male/Female)		6/6	6/6	6/6	6/6	6/6
Liver						
– Centrilobular hypertrophy of hepatocytes	+	0/0	0/0	4/4	0/0	0/0
Kidneys						
– Basophilic tubules	+	0/0	0/0	1/4	0/0	3/1
	++	0/0	0/0	4/0	0/0	2/0
	+++	0/0	0/0	1/1	0/0	1/0
– Granular casts	+	0/0	0/0	5/2	0/0	4/0
	++	0/0	0/0	1/1	0/0	0/0
– Proteinaceous casts	+	0/0	0/0	5/1	0/0	2/0
	++	0/0	0/0	1/0	0/0	0/0

†No histopathological examination was conducted for the 5 and 20 mg/kg scheduled-sacrifice groups. +, mild; ++, moderate; +++, marked.

and DTBP; however, the immature functions involved in the toxicokinetics in newborn rats would be implicated in the higher susceptibility, as in the case of five phenols previously analyzed. While there are very little data on toxicokinetics of environmental chemicals in the newborn, relatively plentiful information has been reported in humans for pharmaceuticals which are clinically applied during the early postnatal period. Recently, Ginsberg *et al.* (2002) conducted comparative analysis of pharmacokinetic parameters for 45 drugs in both children and adults, and showed half-lives in children aged two months or under to generally be two-fold longer than in adults.

As for the susceptibility of the newborn to toxicity of chemicals, although it is generally important to take the sensitivity of target organs and tissues themselves (toxicodynamics) into consideration besides toxicokinetics, there are insufficient data on differences between newborn and young/adult animals. For appearance of toxicity, which is the outcome of toxicokinetics and toxicodynamics, some comparative studies have relied on LD_{50} values (Goldenthal 1971; Sheehan & Gaylor 1990). However, it is not considered that information on acute toxicity at lethal dosage is appropriate when considering the susceptibility of newborn in risk assessment, because dose–response curves could differ, as mentioned above. With prolonged, subtoxic doses, which are basis for TDI or ADI, our series of comparative studies constitute the first systematic assessment, providing an important base for development of new methods of risk assessment of susceptibility of the newborn.

In conclusion, clinical signs and effects on the liver were observed for 2TBP, and hepatic and renal toxicity for DTBP. Although there were no clear differences in toxicity profiles between the newborn and young rats for both chemicals, the toxicity levels differed markedly. The susceptibility of the newborn to these chemicals appears to be 4–5 times higher than that of young animals.

ACKNOWLEDGMENT

The authors gratefully acknowledge the financial support of the Office of Chemical Safety, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labor and Welfare, Japan.

REFERENCES

Adams J (1986) Methods in behavioral teratology. In: Riley EP, Vorhees CV (eds). *Handbook of Behavioral Teratology*. Plenum Press, New York, pp. 67–97.

Ashby J, Lefevre PA (2000) The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of antiandrogens, oestrogens and metabolic modulators. *J Appl Toxicol* **20**: 35–47.

Bartlett MS (1937) Properties of sufficiency and statistical tests. *Proc R Soc Lond Ser A* **160**: 268–282.

Chemical Products' Handbook (2004) *14504 No Kagakushohin*. [Chemical Products of 14504]. The Chemical Daily Co., Ltd, Tokyo. (In Japanese).

Cresteil T, Beaune P, Celier C, Leroux JP, Guengerich FP (1986) Cytochrome P-450 isoenzyme content and monooxygenase activities in rat liver: Effect of ontogenesis and pretreatment by phenobarbital and 3-methylcholanthrene. *J Pharmacol Exp Ther* **236**: 269–276.

Dourson M, Charnley G, Scheuplein R (2002) Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. *Regul Toxicol Pharmacol* **35**: 448–467.

Dunnett CW (1964) New tables for multiple comparisons with a control. *Biometrics* **20**: 482–491.

Fisher RA (1922) On the interpretation of chi-square from contingency tables and the calculation of P. *J R Stat Soc* **85**: 87–94.

Fukuda N, Ito Y, Yamaguchi M *et al.* (2004) Unexpected nephrotoxicity induced by tetrabromobisphenol A in newborn rats. *Toxicol Lett* **150**: 145–155.

Gaytan F, Bellido C, Aguilar R, Aguilar E (1988) Balanopreputial separation as an external sign of puberty in the rat: Correlation with histologic testicular data. *Andrologia* **20**: 450–453.

Gehring PJ, Buerge JF (1969) The distribution of 2,4-dinitrophenol relative to its cataractogenic activity in ducklings and rabbits. *Toxicol Appl Pharmacol* **15**: 574–592.

Ginsberg G, Hattis D, Sonawane B *et al.* (2002) Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. *Toxicol Sci* **66**: 185–200.

Goldenthal EI (1971) A compilation of LD50 values in newborn and adult animals. *Toxicol Appl Pharmacol* **18**: 185–207.

Hirata-Koizumi M, Kusuoka O, Nishimura N *et al.* (2005) Susceptibility of newborn rats to hepatotoxicity of 1,3-dibromopropane and 1,1,2,2-tetrabromomethane, compared with young rats. *J Toxicol Sci* **30**: 29–42.

Hollander M, Wolfe DA (1973) *Nonparametric Statistical Methods*. John Wiley and Sons, New York.

Horster M (1977) Nephron function and perinatal homeostasis. *Ann Rech Vet* **8**: 468–482.

Jensh RP, Brent RL (1988) The effects of prenatal X irradiation on the appearance of reflexes and physiologic markers in the neonatal rat. *Radiat Res* **116**: 416–426.

Koizumi M, Nishimura N, Enami T *et al.* (2002) Comparative toxicity study of 3-aminophenol in newborn and young rats. *J Toxicol Sci* **27**: 411–421.

Koizumi M, Noda A, Ito Y *et al.* (2003) Higher susceptibility of newborn than young rats to 3-methylphenol. *J Toxicol Sci* **28**: 59–70.

Koizumi M, Yamamoto Y, Ito Y *et al.* (2001) Comparative study of toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats. *J Toxicol Sci* **26**: 299–311.

Landrigan PJ, Kimmel CA, Correa A, Eskenazi B (2004) Children's health and the environment: Public health issues and challenges for risk assessment. *Environ Health Perspect* **112**: 257–265.

Matsui M, Watanabe HK (1982) Developmental alteration of hepatic UDP-glucuronosyltransferase and sulphotransferase towards androsterone and 4-nitrophenol in Wistar rats. *Biochem J* **204**: 441–447.

MHLW (2001a) 2-tert-Butylphenol (88-18-6). In: Ministry of Health, Labor and Welfare (ed). *Toxicity Testing Reports of Environmental Chemicals*, **Vol. 8**. Chemical Investigation Promoting Council, Tokyo, pp. 208–218.

MHLW (2001b) 2,4-Di-tert-butylphenol (96-76-4). In: Ministry of Health, Labor and Welfare (ed). *Toxicity Testing Reports of Environmental Chemicals*, Vol. 8. Chemical Investigation Promoting Council, Tokyo, pp. 372–386.

NAS (National Academy of Sciences) (1993) *Pesticides in the Diets of Infants and Children*. National Academy Press, Washington, DC.

New Chemical Index (2001) *Shin Kagaku Index*. [New Chemical Index.] The Chemical Daily Co., Ltd, Tokyo. (In Japanese).

NIHS (1994) *Glossary of Terms for Toxicity Testing*. Biological Safety Research Center, National Institute of Health Sciences, Tokyo. (In Japanese).

OECD (2004) Draft guidance document on reproductive toxicity testing and assessment, OECD environment, health and safety publications series on testing and assessment No. 43. November 10, 2004 (1st Version).

Scheuplein R, Charnley G, Dourson M (2002) Differential sensitivity of children and adults to chemical toxicity. I. Biological basis. *Regul Toxicol Pharmacol* **35**: 429–447.

Shafer TJ, Meyer DA, Crofton KM (2005) Developmental neurotoxicity of pyrethroid insecticides: Critical review and future research needs. *Environ Health Perspect* **113**: 123–136.

Sheehan DM, Gaylor DW (1990) Analysis of the adequacy of safety factors. *Teratology* **41**: 590–591.

Steel RD (1959) A multiple comparison rank sum test: Treatment versus control. *Biometrics* **15**: 560–572.

Takahashi M, Ogata H, Izumi H *et al.* (2004) Comparative toxicity study of 2,4,6-trinitrophenol (picric acid) in newborn and young rats. *Cong Anom* **44**: 204–214.

Zheng Q, Olivier K, Won YK, Pope CN (2000) Comparative cholinergic neurotoxicity of oral chlorpyrifos exposures in preweanling and adult rats. *Toxicol Sci* **55**: 124–132.

Drug and Chemical Toxicology, 31:115–126, 2008

ISSN: 0148-0545 print / 1525-6014 online
DOI: 10.1080/01480540701688808

informa
healthcare

Gonadal Influence on the Toxicity of 2-(2′-Hydroxy -3′,5′-di-*tert*-butylphenyl) benzotriazole in Rats

Mutsuko Hirata-Koizumi,[1] Takashi Matsuyama,[2] Toshio Imai,[1] Akihiko Hirose,[1] Eiichi Kamata,[1] and Makoto Ema[1]

[1]Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan
[2]Shin Nippon Biomedical Laboratories, Ltd., Drug Safety Research Laboratories (SNBL DSR), Kagoshima, Japan

Previously, we showed that susceptibility of male rats to the toxicity of an ultraviolet absorber, 2-(2′-hydroxy-3′,5′-di-*tert*-butylphenyl)benzotriazole (HDBB), was nearly 25 times higher than that of females. In the current study, we investigated the role of sex steroids in the mediation of the gender-related difference using castrated rats. Male and female castrated CD(SD) rats were given HDBB by gavage at 0, 0.5, 2.5, or 12.5 mg/kg/day for 28 days. No deaths, clinical signs of toxicity, or changes in body weight or food consumption were found at any doses. Blood biochemical changes suggestive of hepatic damage, such as increased levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and lactate dehydrogenase, were detected at 12.5 mg/kg/day in males. Absolute and relative liver weight increased at 0.5 mg/kg/day and above in males and at 12.5 mg/kg/day in females. In the liver, histopathological changes, such as nucleolar enlargement, increased mitosis, hypertrophy in hepatocytes, and/or focal necrosis were observed at 0.5 mg/kg/day and above in males, and at 2.5 mg/kg/day and above in females. These findings indicate that castration markedly reduced the gender-related differences in toxicity of HDBB in rats.

Keywords Benzotriazole UV absorber, Castration, Gender-related difference, Rats.

INTRODUCTION

2-(2′-Hydroxy-3′,5′-di-*tert*-butylphenyl)benzotriazole (CAS No. 3846-71-7; HDBB) is an ultraviolet (UV) absorber used in plastic resin products, such as

Address correspondence to Makoto Ema, Division of Risk Assessment, Biological Safety Research Center, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; E-mail: ema@nihs.go.jp

building materials and automobile components (METI, 2006). Previously, we showed a marked difference in the susceptibility of male and female rats to the toxicity of HDBB in 28-day and 52-week repeated oral dose toxicity studies (Hirata-Koizumi et al., 2007; 2008). In the 28-day study, toxic effects in the liver, heart, kidneys, thyroids, and blood were observed. The no observed adverse effect level (NOAEL) for females was 2.5 mg/kg/day based on histopathological changes in the liver and heart detected at 12.5 mg/kg/day. However, the NOAEL for males could not be determined because hepatic changes were noted even at the lowest dose of 0.5 mg/kg/day. In the 52-week study, the NOAEL was concluded to be 0.1 mg/kg/day in males and 2.5 mg/kg/day in females based on histopathological changes in the liver. These findings consistently showed that male rats have a nearly 25 times higher susceptibility to HDBB toxicity than female rats.

Gender-related differences in susceptibility to toxicity have been documented for other substances; for example, a subchronic toxicity study in rats showed that fluoranthene, a polycyclic aromatic hydrocarbon, had greater effects on males than females, especially on the kidneys (Knuckles et al., 2004). In contrast, female rats exhibited greater susceptibility to hypothalamic cholinesterase inhibitory and hypothermic effects of a carbamate cholinesterase inhibitor, rivastigmine (Wang et al., 2001). Such gender-related variations are also reported in humans, mostly for medicines. Examples include the more severe adverse effects, but with greater improvement in response, to antipsychotic drugs such as chlorpromazine and fluspirilene in women (Harris et al., 1995).

Sex hormones are likely to play an important role in gender differences in toxicity responses. In fact, Wang et al. (2001) reported that orchidectomy completely abolished the above-mentioned sex differences in hypothalamic cholinesterase inhibition induced by rivastigmine, and testosterone treatment to gonadectomized males and females decreased the cholinesterase inhibitory effects of rivastigmine; therefore, it is apparent that testosterone interferes with the effects of rivastigmine. On the other hand, estrogen has been shown to act as a dopamine antagonist (Harris et al., 1995), which is considered to contribute, at least in part, to sex differences in response to antipsychotic drugs. The role of sex hormones in differences between sexes in toxicity responses seems to vary from case to case.

In the present study, we performed a repeated dose toxicity study of HDBB using male and female castrated rats to investigate the role of sex steroids in the mediation of sex difference in the susceptibility of rats to the toxicity of HDBB. Administration was conducted in the same way as the previous 28-day study using intact animals (Hirata-Koizumi et al., 2007) for comparison, and effects on the liver and heart, which were principally affected in the previous study of HDBB, were examined.

MATERIALS AND METHODS

This study was performed at Shin Nippon Biomedical Laboratories, Ltd., Drug Safety Research Laboratories (SNBL DSR; Kagoshima, Japan). The experiment was approved by the Institutional Animal Care and Use Committee of SNBL DSR and was performed in accordance with the ethics criteria contained in the bylaws of the Committee of SNBL DSR.

Chemicals

HDBB (Lot no. AY11) was obtained from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). The HDBB used in this study was 100% pure and was kept in a light-resistant and airtight container at room temperature. Test solutions were prepared as suspensions in corn oil twice a week and kept cool in a light-resistant and airtight container until dosing. Stability under refrigerated conditions was confirmed for seven days in the previous 28-day repeated dose toxicity study using intact animals (Hirata-Koizumi et al., 2007). All other reagents used in this study were of specific purity grade.

Animals

Crl:CD(SD) rats (SPF, three weeks old) were purchased from Hino Breeding Center, Charles River Laboratories Japan, Inc. (Yokohama, Japan). All animals were maintained in an air-conditioned room at 21.8–22.8°C, with a relative humidity of 45%–55%, a 12-h light/dark cycle, and ventilation with 15 air changes/h. Animals were housed individually in stainless cages suspended over a cage board. A basal diet (CE-2; CLEA Japan, Inc., Tokyo, Japan) and water, which meets the drinking water standard under the Water Works Law of Japan, were provided *ad libitum*.

Male and female rats were castrated under ether anesthesia between five and eight days after purchase. After a two-week acclimation, they were subjected to treatment at six weeks of age. Rats found to be in good health were selected and assigned to four groups of 10 males and 10 females by stratified random sampling based on body weight. One female in the highest dose group was excluded from the present study because remnants of the left ovary were confirmed at necropsy.

Experimental Design

Male and female castrated rats were given HDBB once-daily at 0 (vehicle control), 0.5, 2.5, and 12.5 mg/kg/day by gavage for 28 days. The dosage levels were determined based on the results of our previous 28-day study using intact rats given HDBB by gavage at 0.5, 2.5, 12.5, or 62.5 mg/kg/day, at which adverse effects, mainly on the liver and heart, were found at all doses in males and at

12.5 mg/kg/day and above in females (Hirata-Koizumi et al., 2007). The volume of each dose was adjusted to 10 mL/kg based on the latest body weight.

All animals were observed daily before and one to two hours after dosing for clinical signs of toxicity. Body weight was measured on days 0, 3, 7, 10, 14, 17, 21, 24, and 28 of the dosing period, and food consumption was recorded on days 0, 3, 7, 10, 14, 17, 21, 24, and 27 of the dosing period.

On the day after the last dosing, blood was drawn from the caudal vena cava in the abdomen with a heparin-added syringe under ether anesthesia and centrifuged to obtain plasma. The plasma was examined for biochemical parameters, such as total protein, albumin, glucose, total cholesterol, triglycerides, total bilirubin, urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine phosphokinase, calcium, inorganic phosphorus, sodium, potassium, and chlorine. Following the collection of blood, all animals were euthanized by exsanguination, and the surface of the body, and organs and tissues of the entire body, were examined macroscopically. The liver and heart were then removed and weighed. Both organs were fixed in 10% neutral-buffered formalin, processed routinely for embedding in paraffin, and sections were prepared for staining with hematoxylin and eosin. Histopathological observation was performed for all groups.

Data Analysis

Parametric data, such as body weight, food consumption, blood biochemical parameters, and organ weights, were analyzed by Bartlett's test (Bartlett, 1937) for homogeneity of distribution ($p < 0.05$). When homogeneity was recognized, Dunnett's test (Dunnett, 1964) was conducted to compare control and individual treatment groups ($p < 0.01$ or 0.05). If not homogenous, the data were analyzed using a Dunnett-type mean rank test ($p < 0.01$ or 0.05) (Hollander and Wolfe, 1973).

RESULTS

No deaths or clinical signs of toxicity were found in any groups. There was no significant difference in body weight between the control and HDBB-treated groups (Fig. 1). Food consumption was also not significantly changed, except for a transient increase on day 21 of the administration period at 12.5 mg/kg/day and on day 27 of the administration period at 2.5 mg/kg/day in males (data not shown).

Blood biochemical examination revealed significant increases in the level of albumin at 0.5 mg/kg/day and above in males and at 2.5 mg/kg/day and above in females, total protein at 0.5 mg/kg/day and above in females, glucose at 12.5 mg/kg/day in males, and BUN at 12.5 mg/kg/day in both sexes (Table 1).



Figure 1: Body weight of male and female castrated rats given HDBB by gavage for 28 days.

Table 1: Blood biochemical findings in male and female castrated rats given HDBB by gavage for 28 days.

Dose (mg/kg/day)	0	0.5	2.5	12.5
Male				
No. of animals	10	10	10	10
Total protein (g/dL)	6.19 ± 0.32	6.44 ± 0.23	6.45 ± 0.40	6.26 ± 0.31
Albumin (g/dL)	4.43 ± 0.18	4.90 ± 0.17**	4.99 ± 0.25**	5.03 ± 0.18**
AST (IU/L)	61.0 ± 6.2	54.4 ± 3.5	63.6 ± 8.0	91.4 ± 24.0**
ALT (IU/L)	40.2 ± 8.9	37.9 ± 4.2	46.2 ± 8.6	55.5 ± 7.2**
ALP (IU/L)	868 ± 200	995 ± 267	989 ± 344	1552 ± 538**
LDH (IU/L)	112 ± 28	129 ± 18	173 ± 30*	403 ± 189**
Glucose (mg/dL)	176 ± 12	199 ± 13**	176 ± 7	196 ± 22*
BUN (mg/dL)	15.8 ± 2.0	15.3 ± 2.1	16.0 ± 1.8	19.7 ± 1.6**
Creatinine (mg/dL)	0.208 ± 0.020	0.174 ± 0.022**	0.176 ± 0.027**	0.175 ± 0.016**
Na (mEq/L)	145 ± 1	145 ± 1	145 ± 1	142 ± 1**
Cl (mEq/L)	107 ± 1	106 ± 2	106 ± 2	104 ± 2**
Female				
No. of animals	10	10	10	9[a]
Total protein (g/dL)	5.81 ± 0.21	6.17 ± 0.26**	6.15 ± 0.18*	6.41 ± 0.34**
Albumin (g/dL)	4.19 ± 0.12	4.39 ± 0.22	4.55 ± 0.19**	5.14 ± 0.32**
AST (IU/L)	54.8 ± 3.5	62.4 ± 5.1*	57.4 ± 6.2	58.4 ± 10.0
ALT (IU/L)	39.1 ± 4.6	43.2 ± 7.8	39.5 ± 5.9	45.8 ± 8.7
ALP (IU/L)	727 ± 164	742 ± 122	703 ± 199	1026 ± 217**
LDH (IU/L)	138 ± 44	254 ± 27**	209 ± 44*	235 ± 116*
Glucose (mg/dL)	202 ± 25	181 ± 13	182 ± 10	216 ± 16
BUN (mg/dL)	20.0 ± 1.6	20.2 ± 2.1	18.2 ± 2.6	23.2 ± 2.2**
Creatinine (mg/dL)	0.230 ± 0.022	0.229 ± 0.025	0.196 ± 0.022*	0.208 ± 0.030
Na (mEq/L)	142 ± 1	143 ± 1	144 ± 1**	141 ± 1
Cl (mEq/L)	104 ± 1	105 ± 2	106 ± 1**	102 ± 2*

Values are expressed as the mean ± SD.
*Significantly different from the control, $p < 0.05$; **significantly different from the control, $p < 0.01$.
[a]One female was excluded because left ovary remnants were found at autopsy.

The levels of LDH at 2.5 mg/kg/day and above in males and at 0.5 mg/kg/day and above in females, ALP at 12.5 mg/kg/day in both sexes, and AST and ALT at 12.5 mg/kg/day in males were also significantly increased. In addition, significant decreases in the levels of creatinine at 0.5 mg/kg/day and above, of sodium at 12.5 mg/kg/day in males, and of chloride at 12.5 mg/kg/day in both sexes were detected.

At necropsy, no gross abnormality was found at any dose. Absolute and relative liver weight was significantly increased at 0.5 mg/kg/day and above in males and at 12.5 mg/kg/day in females (Table 2). No significant change was found in the absolute and relative heart weight.

Histopathological findings in the liver are summarized in Table 3. Diffuse hypertrophy of hepatocytes were observed at 0.5 mg/kg/day and above in males and at 2.5 mg/kg/day and above in females. The cytoplasm of the hepatocytes was slightly eosinophilic. At these doses, anisokaryosis, nucleolar enlargement, and decreased glycogen in hepatocytes were also found. In addition, focal coagulative necrosis at 12.5 mg/kg/day in males and at 2.5 mg/kg/day and above in females, and increased mitosis of hepatocytes at 2.5 mg/kg/day and above and mononuclear cell infiltration at 12.5 mg/kg/day in males, were detected. No substance-related histopathological findings were detected in the heart.

DISCUSSION

The current study was designed to investigate the role of sex steroids in the mediation of gender-related differences in HDBB toxicity. The dosage of HDBB used in the present study was sufficiently high to be expected to induce

Table 2: Organ weight of the heart and liver in male and female castrated rats given HDBB by gavage for 28 days.

Dose (mg/kg/day)	0	0.5	2.5	12.5
Male				
No. of animals	10	10	10	10
Heart (g)	1.30 ± 0.07	1.25 ± 0.09	1.35 ± 0.12	1.37 ± 0.12
	(0.352 ± 0.022)[a]	(0.331 ± 0.028)	(0.362 ± 0.020)	(0.373 ± 0.030)
Liver (g)	15.5 ± 1.5	18.2 ± 2.7*	21.6 ± 3.0**	26.9 ± 1.9**
	(4.18 ± 0.27)	(4.78 ± 0.47*)	(5.76 ± 0.61**)	(7.32 ± 0.40**)
Female				
No. of animals	10	10	10	9[b]
Heart (g)	1.14 ± 0.07	1.11 ± 0.09	1.15 ± 0.10	1.25 ± 0.14
	(0.342 ± 0.027)	(0.322 ± 0.027)	(0.329 ± 0.024)	(0.352 ± 0.035)
Liver (g)	14.5 ± 1.9	14.8 ± 1.4	16.2 ± 2.5	27.0 ± 3.3**
	(4.33 ± 0.34)	(4.28 ± 0.19)	(4.63 ± 0.32)	(7.63 ± 0.87**)

Values are expressed as the mean ± SD.
*Significantly different from the control, $p < 0.05$; **significantly different from the control, $p < 0.01$.
[a]Relative organ weight (g/100 g body weight).
[b]One female was excluded because left ovary remnants were found at autopsy.